Overview

Simultaneous Pancreas-kidney Transplantation With Campath Protocol

Status:
Completed
Trial end date:
2011-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine and compare the efficacy of Campath-1H/Tacrolimus versus ATG/Tacrolimus/MMF therapy in conjunction with initial short-term steroids in Type 1-diabetic patients undergoing simultaneous pancreas-kidney allograft transplantation as well as to evaluate the safety of Campath-1H/Tacrolimus versus ATG/Tacrolimus/MMF in terms of drug-related complications and immunosuppression-associated complications.
Phase:
Phase 3
Details
Lead Sponsor:
Dr. Claudia Bösmüller
Collaborator:
Astellas Pharma GmbH
Treatments:
Alemtuzumab
Methylprednisolone
Tacrolimus
Thymoglobulin